Ones To Watch News
Refine Search
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Biotechnology
Shares of US clinical-stage biotech Vaccinex leapt as much as 233% to an intraday high of $9.56 on Friday, after it disclosed the signing of multi-project deals with two undisclosed prominent pharmaceutical companies. 20 February 2021
Biotechnology
US clinical-stage biopharma company Immunic today announced positive top-line data from an investigator-sponsored Phase II proof-of-concept clinical trial of IMU-838 in primary sclerosing cholangitis (PSC), an uncommon live disease. 18 February 2021
Biotechnology
A new pharmaceutical R&D model was created today, with the merger of 10 privately-held biotech companies with highly validated programs led by industry leading teams to operate under the Centessa umbrella. 17 February 2021
Biotechnology
Where the application of ribonucleic acid (RNA) in medicine is concerned, two companies have so far led the way. 17 February 2021
Biotechnology
US oncology drug developer G1 Therapeutics (Nasdaq: GTHX saw its shares shoot up 20% to $37.15 in after-hours trading on Friday, after it revealed that the US Food and Drug Administration has approved Cosela (trilaciclib). 13 February 2021
Biotechnology
Shares of AC Immune rose nearly 50% yesterday, and were up a further 15% at $8.43 pre-market today, after the Swiss biotech released positive data for its investigational Alzheimer’s vaccine. 12 February 2021
Biotechnology
London, UK-based cell therapy specialist Quell Therapeutics today announced the closing of an extended Series A financing led by its existing investors Syncona, which has committed an additional $34.7 million and UCL Technology Fund (UCLTF), which has committed an additional $1 million; bringing the total Series A financing to circa $84 million. 11 February 2021
Biotechnology
The University of Texas MD Anderson Cancer Center and San Diego-based biotech Mirati Therapeutics have announced a strategic research and development collaboration. 10 February 2021
Biotechnology
UK clinical-stage biotech PureTech Health announced that it has sold 1 million shares of its founded entity, Karuna Therapeutics, through a block trade executed by Morgan Stanley & Co for cash consideration of around $118 million. 10 February 2021
Pharmaceutical
Shares of USA and UK-based KalVista Pharmaceuticals went stratospheric, after the clinical-stage pharma company announced positive top-line Phase II clinical trial results demonstrating statistically- and clinically-significant efficacy of KVD900 as an oral on-demand treatment for hereditary angioedema (HAE) attacks, a rare inherited disorder. 9 February 2021
Biotechnology
US biotech major Gilead Sciences and Gritstone Oncology have entered into a collaboration, option and license agreement to research and develop a vaccine-based immunotherapy as part of Gilead’s efforts to find a curative treatment for human immunodeficiency virus (HIV) infection. 1 February 2021
Biotechnology
French biopharma firm Tollys has appointed Philippe Goupit as chairman of the board of directors. 1 February 2021
Pharmaceutical
Milan, Italy-based Enthera Pharmaceuticals today announced the final closing of its Series A financing, with a total financing of 35 million euros ($42.3 million). 28 January 2021
Generics
The European Investment Bank (EIB) will provide 20 million euros ($24.3 million) to finance the research, development and innovation program of Galenicum, a pharmaceutical company founded in Barcelona, Spain. 27 January 2021
Pharmaceutical
USA-based antibacterial products developer Entasis Therapeutics has announced the availability of an expanded access program (EAP) for sulbactam-durlobactam or SUL-DUR, an investigational drug, for US patients with Acinetobacter baumanni infections, including carbapenem and multidrug resistant strains. 27 January 2021
Biotechnology
A subsidiary of French nanotechnology expert Nanobiotix, Curadigm, has been selected for the Sanofi iTech awards program, as a “highly promising option” to improve gene therapies. 26 January 2021
Pharmaceutical
The US Food and Drug Administration has approved Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis (LN). 25 January 2021
Biotechnology
French drugmaker Servier and UK-based MiNA Therapeutics have announced a research partnership to identify and develop small activating RNA (saRNA) therapies for the treatment of neurological disorders. 21 January 2021
Biotechnology
The National Institute for Health and Care Excellence (NICE) has published a final appraisal determination (FAD) recommending the use of the daily oral pill Jyseleca (filgotinib) on the National Health Service (NHS) in England for moderate to severe active rheumatoid arthritis (RA). 21 January 2021
Biotechnology
California-based Gritstone Oncology saw its shares go stratospherical yesterday, closing up 248.5% at $22.27 and rising a further 19% after-hours, when the biotech firm announced encouraging progress on its COVID-19 vaccine candidate. 20 January 2021
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze